EOLS logo

EOLS Evolus, Inc.

NASDAQ Global Market · Drug Manufacturers - Specialty & Generic · Healthcare

$6.52
-0.48 (-6.86%)

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar …

Market Cap: $431.55Mwww.evolus.com

Price

No data yet.

Social Signal Score

48
5d
—
30d
51
6 mentions
—
60d
45
8 mentions
—
90d
48
9 mentions
—
news: 9

Analyst Ratings

13 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 2Sell 0Strong Sell 0
Avg price target$15+130.1%
Low $13Median $15High $17
Current Consensus

Revenue

$77.95M
$0.00$30.10M$60.20M$90.30M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.45
$-0.48–$-0.44
3 analysts
FY2026
$-0.03
$-0.03–$-0.03
3 analysts
FY2027
$0.33
$0.28–$0.38
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
David Moatazedi
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
353
Beta
1.34
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-1.37
www.evolus.com